Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities

Maria Rita Taliani; Cecilia Becattini; Giancarlo Agnelli; Paolo Prandoni; Marco Moia; Mario Bazzan; RosaMaria Salvi; Walter Ageno; Giuliana Guazzaloca; Davide Imberti; Mauro Silingardi; Renzo Poggio; for the Warfarin Optimal Duration Italian Trial (WODIT) Investigators

doi:10.1160/TH08-07-0477

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(03): 596-598
DOI: 10.1160/TH08-07-0477

Letters to the Editor

Schattauer GmbH

Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities

Authors

Maria Rita Taliani

¹Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
Cecilia Becattini

¹Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
Giancarlo Agnelli

¹Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
Paolo Prandoni

²Dipartimento di Scienze Mediche e Chirurgiche, Università di Padova, Padua, Italy
Marco Moia

³Centro Emofilia e Trombosi, IRCCS Ospedale Maggiore, Milan
Mario Bazzan

⁴Unità di Ematologia e Malattie Trombotiche – Cellini Humanitas, Turin, Italy
RosaMaria Salvi

⁵U.O. Medicina d’Urgenza, Ospedale di Cattinara, Trieste, Italy
Walter Ageno

⁶Dipartimento di Medicina Clinica, Università dell’Insubria, Varese, Italy
Giuliana Guazzaloca

⁷Divisione di Angiologia, Policlinico Sant’ Orsola-Malpighi, Bologna, Italy
Davide Imberti

⁸Thrombosis Center, Emergency Department, Ospedale di Piacenza, Piacenza, Italy
Mauro Silingardi

⁹Divisione di Medicina Interna I, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
Renzo Poggio

¹⁰II Divisione Medicina Generale – Centro Trombosi, Ospedale Galliera, Genova, Italy

for the Warfarin Optimal Duration Italian Trial (WODIT) Investigators

Abstract

Full Text

References

References
1 Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107 (Suppl. 01) I-9-I-16.
2 Weitz JI, Middeldorp S, Geerts W. et al. Thrombophilia and new anticoagulant drugs. Hematology Am Soc Hematol Educ Program 2004; 1: 424-438.
3 Van den Belt AGM, Sanson BJ, Simioni P. et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157: 2227-2232.
4 Kearon C. Long-term management of patients after venous thromboembolism. Circulation 2004; 110 (Suppl. 01) I-10-I-18.
5 Ridker PM, Miletich JP, Stampfer MJ. et al. Factor V Leiden and risk of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2802.
6 Rintelen C, Pabinger I, Knobl P. et al. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haem 1996; 75: 229-232.
7 Simioni P, Prandoni P, Lensing AWA. et al. The risk of recurrent venous thromboembolism in patients with an Arg 506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
8 Eichinger S, Pabinger I, Stumpflen A. et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-628.
9 Baglin C, Brown K, Luddington R. et al. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVL506Q) mutation: effect of warfarin and prediction by precipitating factors. Br J Haematol 1998; 100: 764-768.
10 Eichinger S, Stumpflen A, Hirschl M. et al. Hyper-homocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-569.
11 De Stefano V, Martinelli I, Mannucci PM. et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-806.
12 Lindmarker P, Schulman S, Sten-Linder M. et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 684-689.
13 Kearon C, Gent M, Hirsh J. et al. A Comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
14 Meinardi JR, Middeldorp S, de Kamp PJ. et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002; 116: 625-631.
15 Baglin T, Luddington R, Brown K. et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
16 Santamaria MG, Agnelli G, Taliani MR. et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 2005; 116: 301-306.
17 De Stefano V, Leone G, Mastrangelo S. et al. Clinical manifestations of inherited thrombophilia: a retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-358.
18 Christiansen SC, Cannegieter SC, Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-2361.
19 Ho WK, Hankey GJ, Quinlan DJ. et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
20 Marchiori A, Mosena L, Prins MH. et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114.
21 Young G, Becker S, During C. et al. Influence of the factor V G1691A mutation on symptomatic recurrent venous thromboembolism (VTE) in children: an international multicenter cohort study. J Thromb Haemost. 2008 epub ahead of print.
22 Agnelli G, Prandoni P, Santamaria MG. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-169.
23 Agnelli G, Prandoni P, Becattini C. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Int Med 2003; 139: 19-25.